Ritholtz Wealth Management increased its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 22.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 70,807 shares of the biopharmaceutical company's stock after acquiring an additional 12,750 shares during the period. Ritholtz Wealth Management's holdings in Pfizer were worth $3,712,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Baltimore Washington Financial Advisors Inc. acquired a new stake in shares of Pfizer in the 4th quarter worth about $290,000. Rinkey Investments acquired a new position in Pfizer during the 4th quarter valued at about $32,000. Worth Asset Management LLC acquired a new position in Pfizer during the 1st quarter valued at about $29,000. Bivin & Associates Inc. acquired a new position in Pfizer during the 4th quarter valued at about $37,000. Finally, Stuart Chaussee & Associates Inc. increased its stake in Pfizer by 108.3% during the 1st quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 325 shares during the period. Institutional investors and hedge funds own 67.90% of the company's stock.
Get Pfizer alerts:Pfizer Stock Performance
Shares of PFE opened at $44.08 on Friday. Pfizer Inc. has a one year low of $40.94 and a one year high of $61.71. The company has a 50-day moving average of $48.24 and a two-hundred day moving average of $50.32. The stock has a market cap of $247.39 billion, a price-to-earnings ratio of 8.63, a PEG ratio of 0.54 and a beta of 0.70. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.42 and a quick ratio of 1.20.
Pfizer (NYSE:PFE – Get Rating) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.95 by $0.09. The company had revenue of $27.74 billion during the quarter, compared to analysts' expectations of $26.20 billion. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The business's revenue for the quarter was up 46.8% on a year-over-year basis. During the same period last year, the company posted $1.07 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 6.54 earnings per share for the current year.Pfizer Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Investors of record on Friday, November 4th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 3.63%. The ex-dividend date of this dividend is Thursday, November 3rd. Pfizer's dividend payout ratio is currently 31.31%.
Analysts Set New Price Targets
Several equities analysts have commented on the stock. UBS Group set a $59.00 target price on shares of Pfizer in a research note on Thursday, September 1st. Morgan Stanley lowered their target price on shares of Pfizer from $52.00 to $49.00 and set an "equal weight" rating on the stock in a research note on Friday, July 8th. SVB Leerink lowered their target price on shares of Pfizer from $55.00 to $53.00 and set a "market perform" rating on the stock in a research note on Friday, July 29th. Barclays set a $50.00 price objective on shares of Pfizer in a research note on Thursday, September 1st. Finally, JPMorgan Chase & Co. set a $57.00 price objective on shares of Pfizer in a research note on Tuesday, June 28th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $57.00.
Pfizer Profile
(Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
See Also
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.